Phio Pharmaceuticals CEO to Present at Investor Forum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Source: Globenewswire
- Clinical Progress Update: Phio Pharmaceuticals' lead clinical candidate, PH-762, is being evaluated for skin cancer treatment, with 22 patients completing the Phase 1b trial and demonstrating a 65% pathological response rate, indicating potential market opportunities for the company.
- FDA Engagement Plans: Phio aims to engage with the FDA in Q2 2026 to discuss the next stage of clinical development for PH-762, paving the way for future drug approvals and enhancing investor confidence in the company's prospects.
- Investor Forum Participation: CEO Robert Bitterman will present at the Life Sciences Investor Forum on March 12, 2026, discussing the latest developments of the INTASYL platform and engaging in a live Q&A with investors, aimed at boosting the company's visibility and credibility among investors.
- Strong Financial Position: Phio reported cash and cash equivalents projected to sustain operations into the first half of 2027, providing ample financial support for clinical development and market promotion, thereby strengthening its viability in the competitive biopharmaceutical landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHIO
Wall Street analysts forecast PHIO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.000
Low
14.00
Averages
14.00
High
14.00
Current: 1.000
Low
14.00
Averages
14.00
High
14.00
No data
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Phio Pharmaceuticals CEO to Present at Investor Forum
- Clinical Progress Update: Phio Pharmaceuticals' lead clinical candidate, PH-762, is being evaluated for skin cancer treatment, with 22 patients completing the Phase 1b trial and demonstrating a 65% pathological response rate, indicating potential market opportunities for the company.
- FDA Engagement Plans: Phio aims to engage with the FDA in Q2 2026 to discuss the next stage of clinical development for PH-762, paving the way for future drug approvals and enhancing investor confidence in the company's prospects.
- Investor Forum Participation: CEO Robert Bitterman will present at the Life Sciences Investor Forum on March 12, 2026, discussing the latest developments of the INTASYL platform and engaging in a live Q&A with investors, aimed at boosting the company's visibility and credibility among investors.
- Strong Financial Position: Phio reported cash and cash equivalents projected to sustain operations into the first half of 2027, providing ample financial support for clinical development and market promotion, thereby strengthening its viability in the competitive biopharmaceutical landscape.
See More
Phio Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Beat: Phio Pharmaceuticals reported a FY 2025 GAAP EPS of -$1.45, surpassing expectations by $0.31, indicating an improvement in financial performance despite still being in a loss position.
- Cash Position Improvement: As of December 31, 2025, the company had approximately $21.0 million in cash and cash equivalents, a significant increase from about $5.4 million on December 31, 2024, reflecting substantial progress in financial management and operational efficiency.
- Positive Market Reaction: The earnings beat is likely to positively impact Phio Pharmaceuticals' stock price, attracting more investor interest and enhancing market confidence in the company's prospects.
- Optimistic Future Outlook: With improved cash flow, Phio Pharmaceuticals is positioned to increase R&D investments, accelerating new drug development processes and enhancing the company's long-term growth potential.
See More
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Phio Pharmaceuticals CEO to Present at Investor Forum
- Clinical Progress Update: Phio Pharmaceuticals' lead clinical candidate, PH-762, is being evaluated for skin cancer treatment, with 22 patients completing the Phase 1b trial and demonstrating a 65% pathological response rate, indicating potential market opportunities for the company.
- FDA Engagement Plans: Phio aims to engage with the FDA in Q2 2026 to discuss the next stage of clinical development for PH-762, paving the way for future drug approvals and enhancing investor confidence in the company's prospects.
- Investor Forum Participation: CEO Robert Bitterman will present at the Life Sciences Investor Forum on March 12, 2026, discussing the latest developments of the INTASYL platform and engaging in a live Q&A with investors, aimed at boosting the company's visibility and credibility among investors.
- Strong Financial Position: Phio reported cash and cash equivalents projected to sustain operations into the first half of 2027, providing ample financial support for clinical development and market promotion, thereby strengthening its viability in the competitive biopharmaceutical landscape.
See More
Phio Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Beat: Phio Pharmaceuticals reported a FY 2025 GAAP EPS of -$1.45, surpassing expectations by $0.31, indicating an improvement in financial performance despite still being in a loss position.
- Cash Position Improvement: As of December 31, 2025, the company had approximately $21.0 million in cash and cash equivalents, a significant increase from about $5.4 million on December 31, 2024, reflecting substantial progress in financial management and operational efficiency.
- Positive Market Reaction: The earnings beat is likely to positively impact Phio Pharmaceuticals' stock price, attracting more investor interest and enhancing market confidence in the company's prospects.
- Optimistic Future Outlook: With improved cash flow, Phio Pharmaceuticals is positioned to increase R&D investments, accelerating new drug development processes and enhancing the company's long-term growth potential.
See More
